Acebilustat: meta-analysis of COVID-19 studies

All studies   Hospitalization   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
Meta-analysis1 study · 120 patientsc19early.org

Acebilustat for COVID-19

Serious outcome risk
Acebilustat
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Hospitalization (1)0%
RCTs (1)0%
Early (1)0%
00.511.5+
← Acebilustat
reduces riskIncreased
risk →
c19early.org
October 2026

Acebilustat COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)0%1.00 · 0.06–15.62hosp.1/601/60
Early treatment0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →
c19early.org
October 2026

Acebilustat COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)0%1.00 · 0.06–15.62hosp.1/601/60
Early treatment0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →
c19early.org
October 2026

Acebilustat COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)0%1.00 · 0.06–15.62hosp.1/601/60
Early treatment0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →
c19early.org
October 2026

Acebilustat COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)−67%1.67 · 0.96–2.94no recov.60 (n)60 (n)
Early treatment−67%1.67 · 0.96–2.9060 (n)60 (n)67% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.07
All studies−67%1.67 · 0.96–2.9060 (n)60 (n)67% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.0700.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →
c19early.org
October 2026

Acebilustat COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)0%1.00 · 0.06–15.62hosp.1/601/60
Early treatment0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →
c19early.org
October 2026

Acebilustat COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Levitt (DB RCT)0%1.00 · 0.06–15.62hosp.1/601/60
Early treatment0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.06–15.621/601/600% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Acebilustat
reduces riskAcebilustat
increases risk →